Education
About Us
Working with TipRanks
Follow Us
Surrozen (SRZN)
NASDAQ:SRZN
SRZN Stock Chart & Stats
$15.75
$0.24(1.85%)
At close: 4:00 PM EST
$15.75
$0.24(1.85%)
Day’s Range― - ―
52-Week Range$5.90 - $18.17
Previous CloseN/A
Volume12.23K
Average Volume (3M)25.24K
Market Cap
$107.90M
Enterprise Value-$6.52M
Total Cash (Recent Filing)$81.33M
Total Debt (Recent Filing)$7.08M
Price to Earnings (P/E)―
Beta-0.28
Next Earnings
Mar 19, 2026EPS Estimate
-1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.36
Shares Outstanding8,570,355
10 Day Avg. Volume29,706
30 Day Avg. Volume25,240
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)-1.97
Price to Sales (P/S)3.95
P/FCF Ratio-2.38
Enterprise Value/Market Cap-0.06
Enterprise Value/Revenue-1.81
Enterprise Value/Gross Profit-1.81
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$36.67Price Target Upside132.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market Disruption PotentialSurrozen's novel class of therapies represents a potential disruptor to the $15B global anti-VEGF market, aiming to restore function to damaged retinal tissue through an upstream mechanism.
Mechanistic ValidationSurrozen's Wnt pathway for targeted retinal vascular regeneration has mechanistic validation, reflecting a novel therapeutic direction beyond traditional anti-VEGF.
Significant Near-Term CatalystThe anticipated IND submission for Surrozen's Norrin mimetic and anti-VEGF fusion molecule SZN-8141 is viewed as the most significant near-term platform catalyst, advancing the company's innovative approach in retinal disease treatment.
Bears Say
Surrozen News
SRZN FAQ
What was Surrozen’s price range in the past 12 months?
Surrozen lowest stock price was $5.90 and its highest was $18.17 in the past 12 months.
What is Surrozen’s market cap?
Surrozen’s market cap is $107.90M.
When is Surrozen’s upcoming earnings report date?
Surrozen’s upcoming earnings report date is Mar 19, 2026 which is in 104 days.
How were Surrozen’s earnings last quarter?
Surrozen released its earnings results on Nov 07, 2025. The company reported -$8.36 earnings per share for the quarter, missing the consensus estimate of -$1.135 by -$7.225.
Is Surrozen overvalued?
According to Wall Street analysts Surrozen’s price is currently Undervalued.
Does Surrozen pay dividends?
Surrozen does not currently pay dividends.
What is Surrozen’s EPS estimate?
Surrozen’s EPS estimate is -1.3.
How many shares outstanding does Surrozen have?
Surrozen has 8,570,355 shares outstanding.
What happened to Surrozen’s price movement after its last earnings report?
Surrozen reported an EPS of -$8.36 in its last earnings report, missing expectations of -$1.135. Following the earnings report the stock price went down -3.279%.
Which hedge fund is a major shareholder of Surrozen?
Currently, no hedge funds are holding shares in SRZN
Surrozen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.67 (132.83% Upside)
$36.67 (132.83% Upside)
Hedge Fund Trend
Decreased
By 19.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $8.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
127.85%
Trailing 12-Months
Company Description
Surrozen
Surrozen, Inc. (SRZN) is a biotechnology company focused on harnessing the regenerative properties of the Wnt signaling pathway to develop novel therapeutics. The company is engaged in the research and development of treatments that aim to address unmet medical needs across various therapeutic areas. Surrozen's core products are designed to stimulate tissue regeneration and repair, potentially offering new solutions for diseases where current treatment options are limited.
SRZN Stock 12 Month Forecast
Average Price Target
$36.67
▲(132.83% Upside)
Technical Analysis
Opus Genetics
―
Ovid Therapeutics
―
Shattuck Labs
―
Spruce Biosciences
―
Biomea Fusion
―
Ownership Overview
32.87% Insiders
2.88% Mutual Funds
48.53% Other Institutional Investors
12.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---